Publications by authors named "H Fernandez"

Introduction: The COVID-19 pandemic accelerated the shift from in-person to virtual recruitment, prompting residency and fellowship programs to adopt innovative strategies, such as leveraging social media platforms to attract applicants and enhance visibility. Our aim was to identify and describe the presence of U.S.

View Article and Find Full Text PDF

Phototoxicity of skin due to the application of skincare products or fragrances is increasing from day to day, since a lot of natural extracts, with low or no toxicity in the dark, are being used in the skin exposed to solar radiation. In particular, the use of 4-hydroxy-3-methoxy benzaldehyde, known as vanillin, in the pharmaceutical, food, and cosmetic industries has increased in the last years. This compound is generally considered as safe for humans, and it has been used in a wide range of applications.

View Article and Find Full Text PDF

Rapid Eye Movement (REM) sleep behavior disorder (RBD) affects nearly half of Parkinson's disease (PD) patients. However, the structural heterogeneity within the brainstem, which regulates REM sleep, remains largely unexplored in PD. Our objective was to identify distinct PD subtypes based on microstructural characteristics in the brainstem and examine their associations with the severity of RBD.

View Article and Find Full Text PDF

Introduction: Cognitive symptoms of Parkinson's disease (PD) may initially present subtly, often overshadowed by more noticeable motor symptoms. However, as PD progresses, predicting which individuals will experience significant cognitive decline becomes challenging due to variability, suggesting distinct PD subtypes with varying cognitive trajectories. This study aimed to identify early PD subtypes based on patterns of gray matter atrophy in brain regions associated with cognition and assess their distinct patterns of cognitive change over time.

View Article and Find Full Text PDF

TP53-mutated myeloid disease is a constellation of abnormalities seen in both de novo and therapy-related acute myeloid leukemia and myelodysplastic syndrome. Historically, this group of disorders has had a poor prognosis. Newer treatment combinations allow patients to be treated with less toxicity.

View Article and Find Full Text PDF